VOR BIOPHARMA INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OFPreferred Stock Warrant Agreement • March 14th, 2022 • Vor Biopharma Inc. • Biological products, (no disgnostic substances) • New York
THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between VOR BIOPHARMA INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
VOR BIOPHARMA INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OFCommon Stock Warrant Agreement • March 14th, 2022 • Vor Biopharma Inc. • Biological products, (no disgnostic substances) • New York
THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between VOR BIOPHARMA INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • March 14th, 2022 • Vor Biopharma Inc. • Biological products, (no disgnostic substances) • New York
VOR BIOPHARMA INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OFWarrant Agreement • March 14th, 2022 • Vor Biopharma Inc. • Biological products, (no disgnostic substances) • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between VOR BIOPHARMA INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
VOR BIOPHARMA INC. Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • December 7th, 2022 • Vor Biopharma Inc. • Biological products, (no disgnostic substances)
VOR BIOPHARMA INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • January 15th, 2021 • Vor Biopharma Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (this “Agreement”) is dated as of [ ], 20[ ], and is between Vor Biopharma Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”).
VOR BIOPHARMA INC. Nonstatutory Stock Option Agreement Granted Outside of 2015 Stock Incentive PlanNonstatutory Stock Option Agreement • February 9th, 2021 • Vor Biopharma Inc. • Biological products, (no disgnostic substances)
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • February 1st, 2021 • Vor Biopharma Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 30th day of June, 2020, by and among Vor Biopharma Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
Portions of this agreement (indicated by “[***]”) have been omitted as the Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential....Exclusive License Agreement • December 18th, 2020 • Vor Biopharma Inc. • Biological products, (no disgnostic substances) • New York
This EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), dated April 28, 2016 (the “Effective Date”), is by and between THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, a New York corporation (“Columbia”), and Vor BioPharma Inc., a Delaware corporation (“Company”).
100 CAMBRIDGEPARK DRIVE CAMBRIDGE, MASSACHUSETTS LEASE Between PPF OFF 100 CAMBRIDGE PARK DRIVE, LLC, a Delaware limited liability company (“LANDLORD”) AND VOR BIOPHARMA, INC., a Delaware corporation (“TENANT”) dated as of December 17, 2019Lease • January 15th, 2021 • Vor Biopharma Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Lease Agreement (this “Lease”) is made and entered into as of the 17th day of December, 2019 (the “Effective Date”), by and between PPF OFF 100 CAMBRIDGE PARK DRIVE, LLC, a Delaware limited liability company (“Landlord”) and VOR BIOPHARMA, INC., a Delaware corporation (“Tenant”).
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • December 18th, 2020 • Vor Biopharma Inc. • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Amendment”) is made and entered into as of February 12, 2019 (“Amendment Effective Date”) by and between Vor Biopharma Inc. (“Company”) and The Trustees of Columbia University in the City of New York (“Columbia”).
First Amendment to LeaseLease • June 17th, 2021 • Vor Biopharma Inc. • Biological products, (no disgnostic substances) • Massachusetts
This First Amendment to Lease (this “Amendment”), is made as of the 15th day of June, 2021 (the “Effective Date”), by and between PPF OFF 100 CAMBRIDGE PARK DRIVE, LLC, a Delaware limited liability company, with a business address of c/o Morgan Stanley Real Estate Advisor, Inc., 1585 Broadway, 37th Floor, New York, New York 10036 (the “Landlord”) and VOR BIOPHARMA, INC., a Delaware corporation, with a business address of 100 CambridgePark Drive, Cambridge, Massachusetts 02140 (the “Tenant”).
May 11, 2022 Christopher Slapak, M.D. Via DocuSign/Email Re: Separation Agreement Dear Christopher:Separation Agreement • August 11th, 2022 • Vor Biopharma Inc. • Biological products, (no disgnostic substances) • Massachusetts
This letter sets forth the substance of the separation agreement (hereinafter, “Agreement”) that Vor Biopharma Inc. (hereinafter, the “Company”) is offering to you to aid in your employment transition and retirement from the Company.
Second Amendment to LeaseLease • June 17th, 2021 • Vor Biopharma Inc. • Biological products, (no disgnostic substances)
This Second Amendment to Lease (this “Amendment”), is made as of the 15th day of June, 2021 (the “Effective Date”), by and between PPF OFF 100 CAMBRIDGE PARK DRIVE, LLC, a Delaware limited liability company, with a business address of c/o Morgan Stanley Real Estate Advisor, Inc., 1585 Broadway, 37th Floor, New York, New York 10036 (the “Landlord”) and VOR BIOPHARMA, INC., a Delaware corporation, with a business address of 100 CambridgePark Drive, Cambridge, Massachusetts 02140 (the “Tenant”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 7th, 2022 • Vor Biopharma Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 7, 2022, between Vor Biopharma Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
AT-THE-MARKET EQUITY OFFERING SALES AGREEMENTAt-the-Market Equity Offering Sales Agreement • December 23rd, 2022 • Vor Biopharma Inc. • Biological products, (no disgnostic substances) • New York
Portions of this agreement (indicated by “[***]”) have been omitted as the Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential....Patent License Agreement • January 15th, 2021 • Vor Biopharma Inc. • Biological products, (no disgnostic substances) • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).
Portions of this agreement (indicated by “[***]”) have been omitted as the Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential....Exclusive License Agreement • November 10th, 2021 • Vor Biopharma Inc. • Biological products, (no disgnostic substances)
This SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT ("Second Amendment") is made and entered into as of November 8, 2021 (the “Second Amendment Effective Date”) by and between Vor Biopharma Inc. ("Company") and The Trustees of Columbia University in the City of New York ("Columbia").
